PEA has demonstrated effectiveness for chronic pain of multiple types associated with many painful conditions, especially with neuropathic (nerve) pain, inflammatory pain and visceral pain such as endometriosis and interstitial cystitis.
how PEA works in the body. “It’s an endogenous fatty acid amide produced by the body in response to stressors, pain, and inflammation,” he said. “So it acts as a very good pain reliever for multiple types of pain and inflammation. It’s the body’s own anti-inflammatory and pain-control mechanism as a first responder.”
Not only that, he said, but it is produced throughout the body. “The uniqueness of PEA is that it’s an autacoid,” he said. “Autacoids are produced and used up locally in every tissue; it’s not just produced in one particular organ.” As a result, it’s produced where there is inflammation and pain in the body, he said.
He added that the ingredient is fast-acting (starts working within 15 minutes), and that its half-life is eight hours in the body; however, PEA’s effects are even longer lasting than that, he said. “It prevents the output of inflammatory cytokines and interleukins into your system, and because of this, the effects last longer because it acts on the on the symptoms,” he explained. “The half-life is eight hours in the body, but the effect you get happens throughout the day because it shuts off the of the inflammation and the of the pain.”
The therapeutic efficacy of PEA has been tested in a multitude of indications related to inflammation and pain, and, in both animal models and clinical trials, PEA has proven to be safe and effective.27–35 This compound might become a promising new therapeutic possibility for CRPS, especially considering that its targets are nonneuronal cells: the mast cell and the glia cell.19,36 Both nonneuronal cells have been recognized since the last decade as important contributors to neuropathic pain and neuroinflammation.
Palmitoylethanolamide (PEA) is an endogenous fatty acid amide that, through modulation of mast cells and spinal glial cells activation on peripheral and central nervous system neurons, has been demonstrated to be effective on the different inflammatory mechanisms that develop and maintain both neurogenic and neuropathic pain
PEA . . . performs a great variety of biological functions related to chronic and neuropathic pain and inflammation, as has been demonstrated in clinical trials. These include peripheral neuropathies such as diabetic neuropathy, chemotherapy-induced peripheral neuropathy, carpal tunnel syndrome, sciatic pain, osteoarthritis, low-back pain, failed back surgery syndrome, dental pains, neuropathic pain in stroke and multiple sclerosis, chronic pelvic pain, postherpetic neuralgia, and vaginal pains.
Conclusions: PEA was extremely efficacious on pain and function in a large cohort of patients with low back pain – sciatica.
Conclusions: This observational study provides evidence, albeit preliminary, for the efficacy and safety of um-PEA (Normast) as part of a multimodal therapeutic regimen in the treatment of pain-resistant patients
In summary, available data from rodent and human studies support the safety of PEA in general, and of microPEA specifically, in products intended for human and companion animal consumption.
Conclusion: In spite of the study’s limited sample size and the open-label design, this research suggests the efficacy of um-PEA and m(PEA/PLD) in reducing painful symptomatology and improving quality of life as well as psychological well-being in patients suffering from endometriosis.